Please login to the form below

Not currently logged in
Email:
Password:

diabetic macular oedema

This page shows the latest diabetic macular oedema news and features for those working in and with pharma, biotech and healthcare.

Regeneron and Bayer drop AMD combination

Regeneron and Bayer drop AMD combination

Regeneron has abandoned a combination therapy for age-related macular degeneration after disappointing phase II data, handing an advantage to would-be rival Novartis. ... advance the duo into phase III in either AMD or diabetic macular oedema.

Latest news

More from news
Approximately 3 fully matching, plus 27 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics